Page 8 - க்ளோவர் உதவியாளர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Author Bio Cory is a long-term minded analyst focused on the Healthcare Sector. He genuinely enjoys cutting through the complexity to help everyday investors make better decisions.Follow @coryrenauer Shares of Clover Health (NASDAQ:CLOV) have lost about half of their value since Chamath Palihapitiya s special acquisition company took it public just a few months ago. Despite a few months of lousy performance, enthusiasm for the digital health upstart is still going strong on Wall Street. Bank of America recently reiterated its buy rating on the stock with a $15 price target that suggests it could double your money. A new direct contracting program from the Centers for Medicare and Medicaid Services (CMS) inspired Bank of America analyst Kevin Fischbeck to make such a bold call. Could he be right, or is this just a flash in the pan?

United statesKevin fischbeckChamath palihapitiyaCenters for medicareClover healthMedicaid servicesUnitedhealth groupMedicare advantageProfessional direct contractingAffordable care actAccountable care organizationsDirect contractingClover assistantDirect contactingஒன்றுபட்டது மாநிலங்களில்மையங்கள் க்கு மருத்துவ